Strathspey Crown Holdings LLC announced today the acquisition of the portfolio companies of Novus Via LP, a Nevada-based venture capital investment firm focused on end-stage development and commercialization of advanced electromagnetic and electrochemi…
Uncategorized
NSAIDs may inhibit prostaglandin release in femtosecond cataract surgery
Pretreatment with NSAIDs reduced prostaglandin release in patients undergoing femtosecond laser-assisted cataract surgery, according to a study.“Therefore, it has potential to limit intraoperative laser-induced miosis,” the study authors said. “Previous studies detected elevated prostaglandin levels after femtosecond laser treatment and identified them as a potential mediator for laser-induced miosis.”
No Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: Study
Intravitreal bevacizumab does not alter the long-term outcomes of neovascular glaucoma (NVG), so panretinal photocoagulation (PRP) should remain the mainstay of treatment, according to a retrospective study. Reuters Health Information
21 Health Organizations Join Next Gen of ACOs
(MedPage Today) — New ACO model allows for up to 100% financial risk
The Best of Retina
From anti-VEGF agents to emerging therapies for proliferative vitreoretinopathy, some of the best presentations in retina from this year’s American Academy of Ophthalmology meeting are reviewed. Medscape Ophthalmology
Uncategorized
Acucela to Present at the Biotech Showcase™ 2016 in San Francisco
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that Ryo Kubota, MD, PhD, Chairman, President and CEO, will present this week at the 8th Annual Biotech Showcase™ 2016 in San Francisco, CA. Biotech Showcase™ 2016, one of the industry’s largest annual healthcare investor conferences